Among 36,720 propensity-matched pairs of adults newly starting diabetes therapy, SGLT2 inhibitor initiators had lower rates of major adverse cardiovascular events (HR 0.88), all-cause mortality (HR 0.73), stroke (HR 0.84), cardiac arrest (HR 0.81) and acute heart failure (HR 0.94) than metformin initiators. Myocardial infarction (HR 0.97) and kidney failure requiring replacement therapy (HR 1.00) did not differ.

The heart failure and mortality signals fit what the major SGLT2 trials (EMPA-REG, DAPA-HF, EMPA-KIDNEY) showed, though those enrolled mostly patients already on metformin, so a head-to-head first-line comparison fills a real gap. Still, the 27% mortality reduction is too large to take at face value. Follow-up differed (2.5 versus 3.5 years), the data come from electronic health records, and residual confounding is likely: newer drugs tend to go to patients with better access to care, higher income and closer monitoring, while metformin is often started by default. Target trial emulation reduces immortal-time and selection bias but cannot replace randomization. The null result on kidney failure is also telling, since it suggests the benefit may not reflect the renal protection seen in trials of high-risk patients. Metformin remains cheap, well tolerated and well studied, and guidelines already favor SGLT2 inhibitors for patients with established cardiovascular or kidney disease. This work is confirmatory and hypothesis-strengthening rather than practice-changing, but it supports raising with your doctor whether an SGLT2 inhibitor suits your cardiovascular risk profile.